Close Menu

Autogenomics

Prescient offers a test that is designed to determine an individual's risk of opioid addiction by analyzing 16 genes in the brain's reward pathway.

Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.

The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.

The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.

The companies will also collaborate on new diagnostic technologies and products that are specifically designed for Chinese patients.

The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said. 

The company said it plans to offer 3.75 million shares of its common stock and expects to fetch between $11 and $13 per share in its IPO.

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics has refiled for an initial public offering, less than one year after it pulled earlier plans to go public.

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics and personalized healthcare company Genomas have signed an agreement to develop genetic tests and DNA-guided diagnostic systems to aid in the selection of statins to improve treatment of heart disease, obesity, and diabetes.

Pages

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.